| Literature DB >> 30225211 |
Esra A Akbay1,2, James Kim2,3.
Abstract
Lung cancer accounts for the greatest number of cancer deaths in the world. Tobacco smoke-associated cancers constitute the majority of lung cancer cases but never-smoker cancers comprise a significant and increasing fraction of cases. Recent genomic and transcriptomic sequencing efforts of lung cancers have revealed distinct sets of genetic aberrations of smoker and never-smoker lung cancers that implicate disparate biology and therapeutic strategies. Autochthonous mouse models have contributed greatly to our understanding of lung cancer biology and identified novel therapeutic targets and strategies in the era of targeted therapy. With the emergence of immuno-oncology, mouse models may continue to serve as valuable platforms for novel biological insights and therapeutic strategies. Here, we will review the variety of available autochthonous mouse models of lung cancer, their relation to human smoker and never-smoker lung cancers, and their application to immuno-oncology and immune checkpoint blockade that is revolutionizing lung cancer therapy.Entities:
Keywords: Lung cancer; mouse models; never-smoker; smoker
Year: 2018 PMID: 30225211 PMCID: PMC6131182 DOI: 10.21037/tlcr.2018.06.04
Source DB: PubMed Journal: Transl Lung Cancer Res ISSN: 2218-6751